Hypercalcemia Clinical Trial
Official title:
Hypercalcemia After Cosmetic Paraffin Oil Injections: Unravelling Etiology, Pathogenesis and Potential Treatments
The aim of the study is to characterize paraffin oil induced granulomatous disease. We will investigate pathogenesis and natural history of paraffin disease. Subsequently, through further translational studies, we intend to identify novel treatments to be tested in future randomized clinical trials.
| Status | Recruiting |
| Enrollment | 200 |
| Est. completion date | January 31, 2025 |
| Est. primary completion date | January 31, 2025 |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - previous intramuscular injection of paraffin or other oil Exclusion Criteria: - none |
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Herlev Hospital | Copenhagen |
| Lead Sponsor | Collaborator |
|---|---|
| Herlev Hospital |
Denmark,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of patients with concentration of ionized calcium in plasma above normal range = Hypercalcemia | Hypercalcemia in plasma (exploratory not intervention study). yes or no and level. | at first examination or developed during observation period until 2025 | |
| Primary | Number of patients with concentration of parathyroid hormone PTH in plasma below normal range | PTH level in plasma indicator of hypercalcemia | at first examination or developed during observation period until 2025 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02711059 -
Insulin Resistance in Primary Hyperparathyroidism
|
N/A | |
| Recruiting |
NCT05585593 -
Registry for Hypoparathyroidism Wuerzburg
|
||
| Terminated |
NCT01725113 -
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
|
Phase 4 | |
| Completed |
NCT01460030 -
An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism
|
Phase 3 | |
| Completed |
NCT00325104 -
Cinacalcet to Treat Familial Primary Hyperparathyroidism
|
Phase 3 | |
| Recruiting |
NCT03935984 -
Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
|
Phase 4 | |
| Withdrawn |
NCT01329666 -
Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D
|
Phase 2/Phase 3 | |
| Completed |
NCT00891813 -
Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose
|
Phase 4 | |
| Completed |
NCT00674154 -
Effect of Vitamin D Treatment in Primary Hyperparathyroidism
|
Phase 2/Phase 3 | |
| Completed |
NCT04299425 -
Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy
|
N/A | |
| Completed |
NCT00975221 -
Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy
|
Phase 3 | |
| Withdrawn |
NCT03516747 -
Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland
|
N/A | |
| Completed |
NCT00485706 -
Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients
|
N/A | |
| Recruiting |
NCT01647503 -
Differentially Expressed Proteins in Sporadic Parathyroid Tumors
|
N/A | |
| Completed |
NCT01042626 -
Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects
|
N/A | |
| Not yet recruiting |
NCT01021280 -
Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome
|
N/A | |
| Not yet recruiting |
NCT01226810 -
The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration
|
N/A | |
| Terminated |
NCT00415584 -
Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients
|
Phase 1/Phase 2 | |
| Completed |
NCT00581828 -
Does Treatment of Hypovitaminosis D Increase Calcium Absorption?
|
Phase 4 | |
| Completed |
NCT00126386 -
Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community
|
N/A |